Committees which are required to properly interpret small numbers of events during an individual trial.
Review of natural history studies performed in claudicants indicates that an annual mortality rate of 5% or higher should be anticipated. [5] [6] [7] However, these data may not extrapolate well to current trials for several reasons. First, many of the natural history studies were conducted prior to recognition that lipid-lowering and antiplatelet therapies should be widely used in patients with PAD. Additionally, patients recruited into a claudication clinical trial must meet substantive inclusion and exclusion criteria, which likely result in the exclusion of those patients at highest risk for serious morbidity or fatal cardiovascular events.
To better define expected event rates in claudication trials, data were extracted from published clinical trials of claudication therapies, and adverse events in the placebo arms of these trials were analyzed. These data permitted estimation of expected rates for death, serious adverse events and serious cardiovascular adverse events for patients in trials of claudication therapies. The adverse event experience from these treadmillbased claudication trials was contrasted with data from clinical trials of cardiovascular outcomes in patients with PAD.
Methods

Identification of studies
Randomized, placebo-controlled, double-blinded clinical trials of therapies to improve function in patients with claudication were identified based on a Medline search. As a surrogate method of ensuring relative homogeneity in inclusion-exclusion criteria (for example, the ability to walk on a treadmill), studies included were limited to trials of therapies intended to improve function. Studies published prior to 1990 were not included to minimize heterogeneity in concomitant medications likely to be used (for example, statin and antiplatelet therapies). Similarly, studies examining the effects of statins on walking performance were excluded due to the known effects of statins on mortality and cardiovascular event rates. Studies published only in abstract form were not considered.
The publication reporting each study was reviewed, and the study was included in the current analysis if the number of placebo-treated patients and the duration of therapy could be explicitly determined, the number of patients prematurely withdrawn or lost to follow-up from the placebo arm was less then 20% of the number randomized to placebo, and the data contained at least one of the following values: number of deaths in the placebo arm (all-cause mortality), number of serious adverse events in the placebo arm, or the number of serious cardiovascular adverse events in the placebo arm of the study. Where tabulations were available, events related to lower extremity procedures and complications were excluded from the abstracted serious cardiovascular adverse event numbers.
Analysis of data
For each study, the patient-years of observation were calculated as the number of patients randomized to placebo multiplied by the duration of the study period in years. Where provided, the number of patients in the intention-to-treat population was used. The number of events of interest (death, serious adverse event or serious cardiovascular adverse event) were summed, and divided by the total patient-years exposure for the trials reporting that parameter. Thus, the denominator varied for each of the three analyses. Of note, this method overestimates the actual patient-years of study as premature terminations are ignored.
For comparison, mortality and cardiovascular event rates in patients with PAD were extracted from two large clinical trials conducted since 1990 which did not require treadmill testing (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events, or CAPRIE, 8 and Heart Outcomes Prevention Evaluation, or HOPE 9 ).
Studies published in individual calendar years including at least 100 patient-years of placebo exposure were analyzed for temporal trends in mortality rates. The calculated mortality rate for all trials in a given year was plotted against the year of publication and a linear regression analysis was performed.
Results
Eighteen clinical trials were identified which met the pre-specified criteria. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] All 18 studies provided data on deaths in the placebo arm of the trial, representing over 1400 patient-years of observation ( Table 1 ). The mean ankle-brachial index, a measure of hemodynamic obstruction, was similar across the studies (Table 1) . A total of 27 deaths were reported, for an overall mortality rate of 1.9 per 100 patient-years. A linear regression of study-specific mortality rates versus year of publication suggested that observed mortality rates were not dependent on year of publication (mortality rate per 100 patient-years ϭ -0.0026 ϫ year of publication ϩ5.2390; r ϭ -0.6296, p ϭ 0.255).
Thirteen publications provided data on either serious adverse events or cardiovascular events ( Table 2 ). Serious adverse events were observed at a rate of 24 per 100 patient-years, and cardiovascular events were observed at a rate of 8.5 per 100 patient-years.
Clinical trials designed to reduce mortality and cardiovascular event rates have been reported in which patients with PAD were included as a pre-defined subpopulation. The cumulative mortality rates from the treadmill-based claudication trials were similar to the mortality rates in the placebo and active treatment arms reported in CAPRIE, 8 See 'Methods' for selection criteria. 'n' refers to the number of patients in the placebo arm of the trial. 'ABI' is the mean ankle-brachial index reported for the placebo group in the trial (taken directly from tables and text, or estimated if only provided in graphical form). Mortality rates were calculated as 100 ϫ deaths/(n ϫ study duration). Overall mortality rates were calculated as 100 ϫ total deaths/total patient exposures, where total patient exposure is the sum of the individual n ϫ study duration from each trial (1225 patientyears). The study by Mohler et al 20 reported only cardiovascular deaths, and it was not clear whether this was also total mortality. NP, not provided. Data for serious adverse event numbers and cardiovascular serious adverse event numbers when presented were abstracted and used to calculate rates as done for mortality in Table 1 . Note that study year and duration are provided in Table 1 .
but lower than those
The cumulative patient-years of exposure were 242 for serious adverse events and 637 for cardiovascular serious adverse events. NP, not provided. observed in HOPE 9 (Table 3 ). In contrast, overall cardiovascular event rates in the treadmill-based trials appeared to be higher than in CAPRIE or HOPE (Tables 2 and 3 ). The mean ankle-brachial index of patients with PAD in CAPRIE was 0.57, and was somewhat lower than that observed in treadmill-based trials ( Table 1 ). Of note, CAPRIE only reported cardiovascular deaths, and thus it is likely that total allcause mortality rates would have been higher.
Discussion
Natural history studies suggest that the mortality rate in patients with claudication is 5 per 100 patient-years or greater. [5] [6] [7] In contrast, mortality rates were much lower in the clinical trial populations of claudication drug therapies (Table 1 ). This likely reflects exclusion of the sickest patients from participation in trials, and improved use of statins and antiplatelet therapies since the completion of many of the natural history studies. For example, claudication trials will routinely exclude patients with a recent myocardial infarction, patients whose exercise capacity is limited by heart failure or angina, or patients who have had an amputation. Relevant to these concepts, the observed mortality rates in claudication trials overall tended to be lower than those reported in large cardiovascular outcome trials conducted in patients with PAD, although cardiovascular event rates were similar (Table 3) . Importantly, use of background pharmacotherapies proven to affect cardiovascular event rates may have been higher in the event trials as compared with treadmill-based studies. For example, all patients in CAPRIE were on antiplatelet therapy. 8 Thus, it is likely that experience in previous treadmill-based claudication trials is the best source of data to inform planning for future programs.
The potential utility of the event rates defined in this analysis can be seen in two drug development programs. The number of patients in the clinical trials supporting cilostazol's New Drug Application were sufficiently large to provide evidence of efficacy, but too small to exclude a substantial adverse impact on background cardiovascular event rates. 4 This issue was important due to the theoretical concern that cilostazol's inhibition of phosphodiesterase might increase cardiovascular event rates. 4, 28 Estimates of the expected event rates would have permitted the development program to be adequately powered to address this potential safety concern. The potential for seemingly benign interventions to raise questions of theoretical risk is illustrated by the suggestion that exercise in claudicants induces a prothrombotic state. 29 In a study of avasimibe in patients with claudication, mortality rates of approximately 7.1 per 100 patient-years were observed in patients on the drug, with no deaths in the placebo group. 21 The Data and Safety Monitoring Board felt that the mortality rate on avasimibe was consistent with natural history studies and that the placebo rate was unusually low based on chance. Analysis in the context of the currently calculated event rates may have increased concerns about the safety of avasimibe.
The method used to estimate event rates presented here has significant limitations. The authors did not have access to the clinical trial databases, and thus are dependent on the data reported in publications. Thus, under-reporting of events could have occurred. As multiple trials were combined, heterogeneity in patient populations may have contributed to misleading estimates. However, the range of ankle-brachial indices and event rate estimates from the individual trials were not large, particularly given the small number of events observed in any one trial (Tables 1 and 2 ). Definitions of serious adverse events and cardiovascular events were not independently reviewed, and not all trials used formal adjudication procedures to define events. The designs of the studies reviewed were also heterogeneous. For example, there was substantial variability in the study durations and sample size. This variability may have introduced bias into the data set which could not be fully compensated for by utilizing the patient-years exposure to weight the studies in the overall analysis presented. Finally, the calculations ignore patients not followed for the complete duration of the study, and thus overestimate exposures and underestimates event rates. This absolute error is unlikely to be more than 10-20% of the calculated rates, and thus does not change the conclusions or decrease the utility of the numbers.
In conclusion, death and serious adverse events occur at reasonably high frequency amongst patients with claudication enrolled in clinical trials. However, these event rates appear lower than would have been predicted based on natural history studies in the general population of claudicants. These data will be 144 EP Brass and WR Hiatt Vascular Medicine 2006; 11: 141-145 Table 3 Mortality and cardiovascular event rates in functional versus outcome trials in the peripheral arterial disease population.
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